Report in today's Australian Life Scientist http://www.biotechnews.com.au/index.php?id=1494073475&eid=-2
============================================
Biotech briefs Imugene to commercialise, Viralytics to present, Solbec eyes expansion Dylan Bushell-Embling 09/09/2008 15:07:00
Animal health company Imugene [ASX: IMU] has reported small losses this financial year, but has made progress towards commercialising two products.
The company recorded a net loss of $1.9 million, and a net cash outflow of $1.2 million, and the company said it has developed two animal vaccines with healthy earning potential.
The first, a vaccine for porcine reproductive and respiratory syndrome (PPRS), has been tested and the company is currently seeking licensees. Imugene will soon undergo final trials of the second, a vaccine for coccidiosis in chickens, which will be tested to determine the optimal dosage.
IMU Price at posting:
6.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)